Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoformononetin is a naturally occurring methoxyisoflavone, structurally related to daidzein, and classified as a hydroxyisoflavone and member of the 7-methoxyisoflavones. It is found in plants such as Glycine max (soybean) and Pueraria montana var. lobata (kudzu). Isoformononetin exhibits several biological activities, including acting as an antioxidant, anti-inflammatory agent, bone density conservation agent, apoptosis inhibitor, and immunoprotective compound. Mechanistically, it has been shown to inhibit neuroinflammation by reducing reactive oxygen species (ROS) generation and suppressing activation of the NLR family pyrin domain containing 3 (NLRP3)/ASC/IL‑1 axis in preclinical models. It also modulates apoptotic gene expression (Bax/Bcl2), inhibits Th17 and B-cell differentiation, and demonstrates neuroprotective effects against chemically induced neuronal injury in animal studies[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isoformononetin.